Göttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation

Dalgaard, 2015, Comparison of minipig, dog, monkey and human drug metabolism and disposition, J. Pharmacol. Toxicol. Methods, 74, 80, 10.1016/j.vascn.2014.12.005 Iwasaki, 2019, Importance of cynomolgus monkeys in development of monoclonal antibody drugs, Drug Metab. Pharmacokinet., 34, 55, 10.1016/j.dmpk.2018.02.003 Bettauer, 2011, Systematic review of chimpanzee use in monoclonal antibody research and drug development: 1981-2010, Altex, 28, 103, 10.14573/altex.2011.2.103 Ishigaki, 2018, MHC-identical and transgenic cynomolgus macaques for preclinical studies, Inflamm. Regen., 38, 30, 10.1186/s41232-018-0088-3 Barrow, 2018, Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017, Reprod. Toxicol., 80, 117, 10.1016/j.reprotox.2018.04.008 Carvalho, 2018, Ethical and scientific pitfalls concerning laboratory research with non-human primates, and possible solutions, Animals, 9, 10.3390/ani9010012 Ganderup, 2014, Chapter 3 – Minipig models for toxicity testing and biomarkers, 71 Stirling, 2005, Characterization of the porcine neonatal Fc receptor--potential use for trans-epithelial protein delivery, Immunology, 114, 542, 10.1111/j.1365-2567.2004.02121.x van der Laan, 2010, Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products, J. Pharmacol. Toxicol. Methods, 62, 184, 10.1016/j.vascn.2010.05.005 van Mierlo, 2013, The Gottingen minipig(R) as an alternative non-rodent species for immunogenicity testing: a demonstrator study using the IL-1 receptor antagonist anakinra, J. Immunotoxicol., 10, 96, 10.3109/1547691X.2012.735274 Zheng, 2012, Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration, mAbs, 4, 243, 10.4161/mabs.4.2.19387 Ganderup, 2012, The minipig as nonrodent species in toxicology--where are we now?, Int. J. Toxicol., 31, 507, 10.1177/1091581812462039 Colleton, 2016, The use of minipigs for preclinical safety assessment by the pharmaceutical industry: results of an IQ drusafe minipig survey, Toxicol. Pathol., 44, 458, 10.1177/0192623315617562 Bittner, 2012, Development of a subcutaneous formulation for trastuzumab – nonclinical and clinical bridging approach to the approved intravenous dosing regimen, Arzneim. -Forsch., 62, 401, 10.1055/s-0032-1321831 Harvey, 2011, Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs, Pharm. Res., 28, 107, 10.1007/s11095-010-0123-9 Heining, 2016, The use of minipig in drug discovery and development: pros and cons of minipig selection and strategies to use as a preferred nonrodent species, Toxicol. Pathol., 44, 467, 10.1177/0192623315610823 Grabowski, 2021, Ustekinumab pharmacokinetics after subcutaneous administration in swine model, J. Vet. Sci., 22, 0, 10.4142/jvs.2021.22.e47 Richter, 2020, Subcutaneous site-of-absorption study with the monoclonal antibody tocilizumab in Minipigs: administration behind ear translates best to humans, AAPS J., 22, 63, 10.1208/s12248-020-00446-z van Mierlo, 2014, The minipig as an alternative non-rodent model for immunogenicity testing using the TNFalpha blockers adalimumab and infliximab, J. Immunotoxicol., 11, 62, 10.3109/1547691X.2013.796023 FDA, Guidance for Industry nonclinical safety evaluation of drug or biologic combinations. (2006) 1–16. ICH, Preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1). (2011) 1–23. FDA, Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product Guidance for Industry, (2016) 1–18. Zhang, 2015, ddCt: the ddCt algorithm for the analysis of quantitative real-time PCR (qRT-PCR). R package version 1.26.0, Bioconductor, 1 EMA, Guideline on bioanalytical method validation., (2011). Pipalava, 2019, An update on the animal studies conducted for biosimilar approvals - regulatory requirement vs actual scenario, Regul. Toxicol. Pharmacol.: RTP, 107, 10.1016/j.yrtph.2019.104415 Hovde, 2012, Epidemiology and clinical course of Crohn's disease: results from observational studies, World J. Gastroenterol., 18, 1723, 10.3748/wjg.v18.i15.1723 E. Parliament, 2017, WORKSHOP autoimmune diseases – modern diseases, Policy Dep. A: Econ. Sci. Policy, 1 FDA, Application number 125104 Pharmacology and Tocicology Review and Evaluation, (2004) 1–100. Grabowski, 2019, Fluctuations in pharmacokinetics profiles of monoclonal antibodies, Eur. J. Drug Metab. Pharmacokinet., 10.1007/s13318-019-00548-w Oravec, 1995, Normal human polyspecific immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro, Nephrol., Dial., Transplant.: Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc., 10, 796 Ronda, 1994, Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus, Int. Immunol., 6, 1651, 10.1093/intimm/6.11.1651 Dawson, 2018, Porcine cluster of differentiation (CD) markers 2018 update, Res. Vet. Sci., 118, 199, 10.1016/j.rvsc.2018.02.007 Lee, 2020, Comparative analysis of immune related genes between domestic pig and germ-free minipig, Lab Anim. Res., 36, 44, 10.1186/s42826-020-00077-7 Defer, 2012, Mauff, CD49d expression as a promising biomarker to monitor natalizumab efficacy, J. Neurol. Sci., 314, 138, 10.1016/j.jns.2011.10.005 EMA, Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, EMEA/CHMP/BMWP/42832/2005 Rev1 (2015) 1–13. FDA, 21 CFR Ch. I PART 3-PRODUCT JURISDICTION Subpart A Assignment of Agency Component for Review of Premarket Applications, § 3.1 (2010) 56–60. Ala, 2013, Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates, Dig. Dis. Sci., 58, 2528, 10.1007/s10620-013-2755-1 Videm, 2008, Soluble ICAM-1 and VCAM-1 as markers of endothelial activation, Scand. J. Immunol., 67, 523, 10.1111/j.1365-3083.2008.02029.x